A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure.

Trial Profile

A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2011

At a glance

  • Drugs Cenderitide (Primary)
  • Indications Decompensated heart failure
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms CONDITION-HF
  • Most Recent Events

    • 15 Aug 2011 All subjects have been enrolled in the low-dose cohort in Part B of the study, according to a Nile Therapeutics media release. Enrolment is expected to be completed in quarter 4 of 2011.
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 14 Mar 2011 Results will be presented at the American College of Cardiology Scientific Sessions, according to a Nile Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top